Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-337-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
Studies on kinetics in the dossier
An in vivo toxicokinetic study (Klimisch 2; no guideline study) with14C-labeled resorcinol bis-diphenyl phosphate (RDP) has been performed in several species and via various routes: rat (IV, inhalation, dermal, oral), mouse (Intravenous), and monkey (IV, dermal). (McCormick, 1997). The level of radioactivity was measured in plasma, faeces, urine, expired air, and in several tissues.
Systemic delivery of RDP was highest when the compound was administered intravenously, followed by the inhalation, oral, and dermal route (in order). The absorption rates are based on the AUC compared with IV.
The rat study shows an inhalatory absorption of ca 60%. As the estimated retention in the lungs is 25% (of applied dose), this should be considered as a worst case value.
The oral absorption in the rat was ca 58% (based on the AUC compared with IV) (McCormick, 1997).
After dermal exposure in the rat the dermal absorption was estimated to be 15% (based on the AUC compared with IV) (McCormick, 1997). Thjs is in line with the dermal absorption which was reported in an earlier study, in which an absorption of 17% was observed in rats (Little, 1994). The Monkey study reported a lower or no dermal absorption (<9%) (McCormick, 1997). However this is disputable because of a low recovery (67%), probably due to the study design. Therefore, the value found in rats will be used for risk assessment.
Distribution of RDP was studied after intravenous injection in the rat (IV dose of 100mg/kg). RDP was mainly distributed to the lungs (ca 5-10%). Tissues other than lungs demonstrated comparable levels of radioactivity, with liver and fat showing slightly more radioactivity than other tissues and carcass, and the brain showing less radioactivity.
All IV studies (mouse, rat, monkey) show that the primary route of elimination is the faeces (ca 50%) and secondary the urine. A minimum is excreted via expired air. In the rat after IV-, oral- and inhalatory exposure a half-life of ca 2,5 days was reported. After dermal exposure half-life was slightly higher (3,7 days).
Physicochemical properties
The available physicochemical properties can provide useful information regarding the behaviour of RDP in the body (based on the REACH Guidance on Information Requirements and Chemical Safety Assessment Chapter R.7c Endpoint Specific Guidance).
The molecular weight of RDP is indicative for readily absorption after oral administration. This might occur by micellular solubilisation, due to the moderate till high log Kow and despite of the poor water solubility. This is in line with the observed oral absorption in rats.
Although respiratory exposure is unlikely to occur on a large scale due to the low vapour pressure of RDP, some respiratory exposure and absorption (aerosols, comparable to oral absorption) may be expected, which is in line with the observed respiratory absorption in rats.
The physical state of RDP (liquid), the low vapour pressure and to a lesser extent the molecular weight indicates that dermal absorption is possible. The poor water solubility and rather high log Kow are an indication for a high uptake into the stratum corneum, but a limited rate of penetration from the stratum to the epidermis. This is confirmed by the available dermal absorption studies in rats.
Conclusions
Based on an extensive toxicokinetics study, RDP is expected to be absorbed after oral and inhalatory exposure (58 and 60%, respectively). Dermal absorption is limited (17%). Studies indicate that RDP is slowly metabolized. The main excretion route is the faeces (ca 50%) and the urine.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.